×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVIR – atea pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVIR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/7
12:10 pm
avir
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
3/6
06:16 pm
avir
https://seekingalpha.com/article/4765490-atea-pharmaceuticals-inc-avir-q4-2024-earnings-call-transcript [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4765490-atea-pharmaceuticals-inc-avir-q4-2024-earnings-call-transcript [Seeking Alpha]
3/6
05:21 pm
avir
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
3/6
04:05 pm
avir
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Low
Report
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2/27
07:00 am
avir
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
Medium
Report
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
2/24
08:04 am
avir
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors [Yahoo! Finance]
2/24
07:00 am
avir
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
Medium
Report
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
1/13
07:00 am
avir
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
3/6/2025
04:05 pm
avir
atea pharmaceuticals, inc. - common stock
MISS
Report
-0.3%
atea pharmaceuticals, inc. - common stock
3/6/2025
04:05 pm
avir
atea pharmaceuticals, inc. - common stock
MISS
Report
-0.3%
atea pharmaceuticals, inc. - common stock
3/6/2025
04:05 pm
avir
atea pharmaceuticals, inc. - common stock
MISS
Report
-0.3%
atea pharmaceuticals, inc. - common stock
3/6/2025
04:05 pm
avir
atea pharmaceuticals, inc. - common stock
MISS
Report
-0.3%
atea pharmaceuticals, inc. - common stock
Date
Time
Symbol
Headline
Impact
3/6
04:47 pm
avir
Form 10-K Atea Pharmaceuticals, For: Dec 31
Low
Report
Form 10-K Atea Pharmaceuticals, For: Dec 31
3/6
04:46 pm
avir
Form 8-K Atea Pharmaceuticals, For: Mar 06
Low
Report
Form 8-K Atea Pharmaceuticals, For: Mar 06
3/4
09:27 am
avir
Form SCHEDULE 13D Atea Pharmaceuticals, Filed by: Radoff Bradley Louis
Low
Report
Form SCHEDULE 13D Atea Pharmaceuticals, Filed by: Radoff Bradley Louis
2/24
06:52 pm
avir
Form 4 Atea Pharmaceuticals, For: Feb 20 Filed by: Kirsch Arthur S
Neutral
Report
Form 4 Atea Pharmaceuticals, For: Feb 20 Filed by: Kirsch Arthur S
2/24
06:47 pm
avir
Form 3 Atea Pharmaceuticals, For: Feb 20 Filed by: Kirsch Arthur S
Neutral
Report
Form 3 Atea Pharmaceuticals, For: Feb 20 Filed by: Kirsch Arthur S
2/24
08:17 am
avir
Form 8-K Atea Pharmaceuticals, For: Feb 20
Medium
Report
Form 8-K Atea Pharmaceuticals, For: Feb 20
2/14
12:47 pm
avir
Form SCHEDULE 13G/A Atea Pharmaceuticals, Filed by: EcoR1 Capital, LLC
Low
Report
Form SCHEDULE 13G/A Atea Pharmaceuticals, Filed by: EcoR1 Capital, LLC
2/4
06:00 pm
avir
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Vavricka John
Medium
Report
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Vavricka John
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/7
Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc.
20.6%
1/12 Form 8-K Aviragen Therapeutics, For: Jan 11 13.6%
11/29 Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 10.2%
1/17 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. 4.8%
11/7 Form 10-Q Aviragen Therapeutics, For: Sep 30 3.8%
2/6 Form 8-K Aviragen Therapeutics, For: Feb 06 3.3%
1/3 Form 424B3 Aviragen Therapeutics, 2.7%
2/7 Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders 2.0%
11/6 Aviragen Therapeutics, Inc. (NASDAQ: AVIR) had its "hold" rating re-affirmed by analysts at HC Wainwright. 1.8%
12/12 Form S-4 Aviragen Therapeutics, 1.7%
1/12 Form 8-K Aviragen Therapeutics, For: Jan 11 13.6%
11/29 Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 10.2%
1/17 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. 4.8%
11/7 Form 10-Q Aviragen Therapeutics, For: Sep 30 3.8%
2/6 Form 8-K Aviragen Therapeutics, For: Feb 06 3.3%
1/3 Form 424B3 Aviragen Therapeutics, 2.7%
2/7 Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders 2.0%
11/6 Aviragen Therapeutics, Inc. (NASDAQ: AVIR) had its "hold" rating re-affirmed by analysts at HC Wainwright. 1.8%
12/12 Form S-4 Aviragen Therapeutics, 1.7%
TOP News Decliners
2/13
Form SC 13G/A Aviragen Therapeutics, Filed by: Broadfin Capital, LLC
-8.7%
2/9 BRIEF-Aviragen Adjourns Special Meeting Of Stockholders [Reuters] -7.3%
2/1 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. -7.1%
2/6 Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018 -6.0%
12/29 Form SC 13D Aviragen Therapeutics, Filed by: DIGIRAD CORP -5.2%
1/29 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.7%
1/12 Form PREC14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.4%
1/18 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -4.3%
1/24 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -3.0%
11/9 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -2.7%
2/9 BRIEF-Aviragen Adjourns Special Meeting Of Stockholders [Reuters] -7.3%
2/1 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. -7.1%
2/6 Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018 -6.0%
12/29 Form SC 13D Aviragen Therapeutics, Filed by: DIGIRAD CORP -5.2%
1/29 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.7%
1/12 Form PREC14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.4%
1/18 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -4.3%
1/24 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -3.0%
11/9 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: